| CLX |
Report |
Fiscal Q4 2026 adjusted EPS |
IN-LINE |
pred ~$1.68 vs. cons $1.67 |
MEDIUM |
| CLX |
Report |
Fiscal Q4 2026 net sales |
IN-LINE |
pred ~$1.91B vs. cons $1.913B |
HIGH |
| CLX |
Report |
Fiscal Q4 2026 gross margin |
IN-LINE |
pred ~41.7% vs. cons 41.5% |
MEDIUM |
| CLX |
Guide |
Adjusted EPS |
LOWER |
guide ~$5.65 vs. cons $6.00 (FY2027) |
HIGH |
| CLX |
Guide |
Net sales |
LOWER |
guide ~$7.42B vs. cons $7.57B (FY2027) |
MEDIUM |
| CLX |
Guide |
Organic sales growth |
LOWER |
guide ~1.0% vs. cons 3.0% (FY2027) |
MEDIUM |
| CLX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-6.5% |
— |
HIGH |
| CLX |
Return |
5-day cumulative residual |
-8.5% (FOLLOW-THROUGH) |
FY2027 adjusted-EPS guidance of ~$5.65 versus ~$6.00 consensus implies roughly 6% estimate cuts; weak organic-growth and margin assumptions should outweigh an approximately in-line Q4 and drive continued downward revisions. |
MEDIUM |